Updated:
Hoth Therapeutics
Hoth Therapeutics, Inc. is a publicly traded biopharmaceutical company. The firm has not publicly disclosed founding principals, AUM, or investment strategy...
Hoth Therapeutics
Hoth Therapeutics, Inc. is a publicly traded biopharmaceutical company. The firm has not publicly disclosed founding principals, AUM, or investment strategy details. Public filings indicate it focuses on drug development, though no specific portfolios or recent deployment data are available. The firm's strategy and asset-class mix are not disclosed in public records. No named portfolio companies, deals, or co-investors are identifiable from verifiable sources. Geographic footprint and team size remain unreported. As of mid-2026, no recent operational events have been confirmed. The firm does not appear to operate additional offices, philanthropic structures, or adjacent investment vehicles based on available information. The firm's public status as a corporation differentiates it from typical family offices, but no structural details about governance, succession, or sourcing models are verifiable.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
—
Country
—
City
—
Corporate office
—
Frequently asked questions
Is Hoth Therapeutics structured as a family office?
Hoth Therapeutics, Inc. is a publicly traded biopharmaceutical company listed on the NASDAQ under the ticker HOTH. Public filings describe it as a drug development company, not a family office. No disclosures indicate single-family or multi-family office operations.
Does Hoth Therapeutics manage outside capital?
As a public company, Hoth Therapeutics raises capital through equity offerings and may attract institutional investors, but it does not publicly report managing third-party assets as a fund or family office.
What therapeutic areas does Hoth Therapeutics focus on?
The firm's public statements mention development of therapies for conditions including skin diseases and oncology. No specific portfolio companies or drug candidates are confirmed through verifiable primary sources.
Who leads investment decisions at Hoth Therapeutics?
No named CEO, CIO, or managing principal is verifiable through public records. The firm's SEC filings list officers, but their roles in capital allocation are not disclosed.
How does Hoth Therapeutics source deal flow?
No information is publicly available regarding proprietary sourcing, partnerships, or co-investment strategies. The firm's business development pipeline is not disclosed.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: